🚀 VC round data is live in beta, check it out!
Olema Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Olema Pharmaceuticals and similar public comparables like AtaiBeckley, Lepu Biopharma, Ab&B Bio-Tech, Caplin Point Laboratories and more.
Olema Pharmaceuticals Overview
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Founded
2006
HQ
Employees
96
Website
Financials (LTM)
EV
$962M
Olema Pharmaceuticals Financials
Olema Pharmaceuticals reported last 12-month revenue of $666K and negative EBITDA of ($184M).
In the same LTM period, Olema Pharmaceuticals generated $533K in gross profit, ($184M) in EBITDA losses, and had net loss of ($176M).
Revenue (LTM)
Olema Pharmaceuticals P&L
In the most recent fiscal year, Olema Pharmaceuticals reported revenue of — and EBITDA of ($171M).
Olema Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $666K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $533K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($184M) | XXX | ($171M) | XXX | XXX | XXX |
| EBITDA Margin | (27669%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (28469%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($176M) | XXX | ($162M) | XXX | XXX | XXX |
| Net Margin | (26486%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Olema Pharmaceuticals Stock Performance
Olema Pharmaceuticals has current market cap of $1B, and enterprise value of $962M.
Market Cap Evolution
Olema Pharmaceuticals' stock price is $16.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $962M | $1B | 1.9% | XXX | XXX | XXX | $-1.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOlema Pharmaceuticals Valuation Multiples
Olema Pharmaceuticals trades at 1445.2x EV/Revenue multiple, and (5.2x) EV/EBITDA.
EV / Revenue (LTM)
Olema Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Olema Pharmaceuticals has market cap of $1B and EV of $962M.
Equity research analysts estimate Olema Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Olema Pharmaceuticals has a P/E ratio of (8.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $962M | XXX | $962M | XXX | XXX | XXX |
| EV/Revenue | 1445.2x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (5.2x) | XXX | (5.6x) | XXX | XXX | XXX |
| EV/EBIT | (5.1x) | XXX | (5.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 1806.5x | XXX | — | XXX | XXX | XXX |
| P/E | (8.3x) | XXX | (9.0x) | XXX | XXX | XXX |
| EV/FCF | (5.5x) | XXX | (6.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Olema Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Olema Pharmaceuticals Margins & Growth Rates
Olema Pharmaceuticals' revenue in the last 12 month grew by 1267%.
Olema Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.9M for the same period.
Olema Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1267% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (27669%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3399% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 25202% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Olema Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Olema Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| AtaiBeckley | XXX | XXX | XXX | XXX | XXX | XXX |
| Lepu Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ab&B Bio-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Caplin Point Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Novavax | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Olema Pharmaceuticals M&A Activity
Olema Pharmaceuticals acquired XXX companies to date.
Last acquisition by Olema Pharmaceuticals was on XXXXXXXX, XXXXX. Olema Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Olema Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOlema Pharmaceuticals Investment Activity
Olema Pharmaceuticals invested in XXX companies to date.
Olema Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Olema Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Olema Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Olema Pharmaceuticals
| When was Olema Pharmaceuticals founded? | Olema Pharmaceuticals was founded in 2006. |
| Where is Olema Pharmaceuticals headquartered? | Olema Pharmaceuticals is headquartered in United States. |
| How many employees does Olema Pharmaceuticals have? | As of today, Olema Pharmaceuticals has over 96 employees. |
| Who is the CEO of Olema Pharmaceuticals? | Olema Pharmaceuticals' CEO is Sean P. Bohen. |
| Is Olema Pharmaceuticals publicly listed? | Yes, Olema Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Olema Pharmaceuticals? | Olema Pharmaceuticals trades under OLMA ticker. |
| When did Olema Pharmaceuticals go public? | Olema Pharmaceuticals went public in 2020. |
| Who are competitors of Olema Pharmaceuticals? | Olema Pharmaceuticals main competitors are AtaiBeckley, Lepu Biopharma, Ab&B Bio-Tech, Caplin Point Laboratories. |
| What is the current market cap of Olema Pharmaceuticals? | Olema Pharmaceuticals' current market cap is $1B. |
| What is the current revenue of Olema Pharmaceuticals? | Olema Pharmaceuticals' last 12 months revenue is $666K. |
| What is the current revenue growth of Olema Pharmaceuticals? | Olema Pharmaceuticals revenue growth (NTM/LTM) is 1267%. |
| What is the current EV/Revenue multiple of Olema Pharmaceuticals? | Current revenue multiple of Olema Pharmaceuticals is 1445.2x. |
| Is Olema Pharmaceuticals profitable? | No, Olema Pharmaceuticals is not profitable. |
| What is the current EBITDA of Olema Pharmaceuticals? | Olema Pharmaceuticals has negative EBITDA and is not profitable. |
| What is Olema Pharmaceuticals' EBITDA margin? | Olema Pharmaceuticals' last 12 months EBITDA margin is (27669%). |
| What is the current EV/EBITDA multiple of Olema Pharmaceuticals? | Current EBITDA multiple of Olema Pharmaceuticals is (5.2x). |
| What is the current FCF of Olema Pharmaceuticals? | Olema Pharmaceuticals' last 12 months FCF is ($175M). |
| What is Olema Pharmaceuticals' FCF margin? | Olema Pharmaceuticals' last 12 months FCF margin is (26280%). |
| What is the current EV/FCF multiple of Olema Pharmaceuticals? | Current FCF multiple of Olema Pharmaceuticals is (5.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.